Separately, HC Wainwright lowered shares of Neovasc from a buy rating to a neutral rating in a report on Wednesday.
Neovasc Stock Performance
Neovasc has a 1-year low of C$0.49 and a 1-year high of C$6.07. The company’s 50 day moving average is C$1.78.
Insider Activity at Neovasc
In other news, Director Paul Geyer acquired 3,000 shares of the business’s stock in a transaction on Friday, November 18th. The shares were purchased at an average cost of C$8.71 per share, with a total value of C$26,130.00. Following the acquisition, the director now directly owns 18,335 shares of the company’s stock, valued at C$159,697.85.
Neovasc Company Profile
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.